Hologic Inc.'s and Grifols SA'sProcleix Zika Virus blood screening assay, and Roche Molecular Diagnostics' cobas Zika Assay on the cobas 6800/8800 systems – operating under US FDA investigational new drug (IND) applications – will be the primary tests used to screen the entire US donated blood supply for the Zika virus over the next 12 weeks, FDA confirmed at an Aug. 26 briefing.
"What I can tell you about use [of these tests] is that FDA has evaluated the information submitted to us, and that we have confidence they will perform appropriately as...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?